Predict your next investment

Corporation
HEALTHCARE | Pharmaceuticals / Drugs
ty1970.com

See what CB Insights has to offer

Stage

Corporate Majority

Investors Count

2

Deal Terms

1

Portfolio Exits

1

Tianyuan Pharmaceutical Funding, Tianyuan Pharmaceutical Valuation & Tianyuan Pharmaceutical Revenue

3 Fundings

Tianyuan Pharmaceutical's latest funding round was a Corporate Majority for $29.37M on September 30, 2019.

Tianyuan Pharmaceutical's latest post-money valuation is from September 2019.

Sign up for a free 30-day trial to see Tianyuan Pharmaceutical's valuations in September 2019 and more.

Date

Round

Amount

Investors

Valuation
Valuations are submitted by companies, mined from state filings or news, provided by VentureSource, or based on a comparables valuation model.

Revenue

Sources

9/30/2019

Corporate Majority

$29.37M

$99M

$0.00B

((9.99x))

FY 1234

1

5/15/2018

Take Private

$99M

$0.00B

((9.99x))

FY 1234

10

5/6/2015

IPO

$99M

$0.00B

((9.99x))

FY 1234

10

Date

9/30/2019

5/15/2018

5/6/2015

Round

Corporate Majority

Take Private

IPO

Amount

$29.37M

$99M

$99M

Investors

Valuation

$99M

Revenue

$0.00B

((9.99x))

FY 1234

$0.00B

((9.99x))

FY 1234

$0.00B

((9.99x))

FY 1234

Sources

1

10

10

Tianyuan Pharmaceutical Deal Terms

1 Deal Term

Tianyuan Pharmaceutical's deal structure is available for 1 funding round, including their Corporate Majority from September 30, 2019.

Round

Corporate Majority

Funding Date

Pre-Money Valuation

Post-Money Valuation

Amount Raised

Shares Authorized

Issuance Price

Dividend Rate

Liquidation Preferences

Liquidation Price

Participation

Conversion Price

Anti Dilution

General Voting

Board Voting

Par Value

Round

Funding Date

Pre-Money Valuation

Post-Money Valuation

Amount Raised

Shares Authorized

Issuance Price

Dividend Rate

Liquidation Preferences

Liquidation Price

Participation

Conversion Price

Anti Dilution

General Voting

Board Voting

Par Value

Corporate Majority

Tianyuan Pharmaceutical Investors

2 Investors

Tianyuan Pharmaceutical has 2 investors. Goldenmax invested in Tianyuan Pharmaceutical's Corporate Majority funding round.

First funding

Last Funding

Investor

Rounds

Board Seats

Type

Location

9/30/2019

9/30/2019

1
Corporate Majority

Corporation

China

00/00/0000

00/00/0000

Subscribe to see more

Subscribe to see more

Subscribe to see more

Corporation

China

First funding

9/30/2019

00/00/0000

Last Funding

9/30/2019

00/00/0000

Investor

Subscribe to see more

Rounds

1
Corporate Majority

Subscribe to see more

Board Seats

Subscribe to see more

Type

Corporation

Corporation

Location

China

China

Tianyuan Pharmaceutical Acquisitions

1 Acquisition

Tianyuan Pharmaceutical acquired 1 company. Their latest acquisition was Tianyuan Pharmaceutical on May 15, 2018.

Date

Investment Stage

Companies

Valuation
Valuations are submitted by companies, mined from state filings or news, provided by VentureSource, or based on a comparables valuation model.

Total Funding

Note

Sources

5/15/2018

Take Private

Take Private

1

Date

5/15/2018

Investment Stage

Take Private

Companies

Valuation

Total Funding

Note

Take Private

Sources

1

Tianyuan Pharmaceutical Portfolio Exits

1 Portfolio Exit

Tianyuan Pharmaceutical has 1 portfolio exit. Their latest portfolio exit was Tianyuan Pharmaceutical on September 30, 2019.

Date

Exit

Companies

Valuation
Valuations are submitted by companies, mined from state filings or news, provided by VentureSource, or based on a comparables valuation model.

Acquirer

Sources

9/30/2019

Corporate Majority

$991

1

Date

9/30/2019

Exit

Corporate Majority

Companies

Valuation

$991

Acquirer

Sources

1

CB Insights uses Cookies

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.